Introduction 

Genes are segments of DNA that form our body’s blueprint. In genetic conditions, mutations can turn genes on or off, altering a person’s entire genetic makeup. Loeys-Dietz Syndrome (LDS) is a rare inherited genetic condition that affects connective tissue. The mutated genes are involved in several body systems:

• The heart
• Blood vessels 
• Skin 
• Bones 

The defining characteristic is an enlarged aorta, the blood vessel that pumps blood to the whole body. Here, the aorta walls stretch and weaken, resulting in bulges and tears in the vessel walls. This strain often leads to aneurysms in the aorta. The tears and strains spread throughout the vessels in the body, causing abnormal twists and turns. 

This has several physical manifestations across the body:

• Widely spaced eyes 
• Club foot 
• Translucent skin 
• Easy bleeding 
• Easy bruising 
• Scarring problems
• Scoliosis 
• Aneurysms in the aortic root¹

LDS is an autosomal dominant genetic condition. This means that only one copy of the mutated gene is required to cause this disorder. If one parent possesses the mutated gene, the child has a 50% chance of inheriting LDS. In most cases, the genetic mutation occurs spontaneously in people with no family history.²

The genes affected in this condition are involved in the TGFß signalling pathway. 5 types of mutated genes within this pathway cause different types of LDS. Each type has distinct features, but some symptoms overlap. The 5 main versions of LDS are as follows: 

• LDS-I (TGFßR1): involves the head and face features. 
• LDS-II (TGFßR2): type II and impacts the skin 
• LDS-III (SMAD-3): type III and causes aneurysms 
• LDS-IV (TGFß2): results in aortic abnormalities. 
• LDS-V (TGFß3): affects the abdominal aorta region²

Out of these 5 variations, types I and II are the most common. 

This article will explore the genetic basis of LDS and the role of specific signalling pathways in its development. 

Genetic basis of loeys-dietz syndrome

LDS is caused by a mutation in one of the five genes which encode for the receptors and other molecules of the TGFß signalling pathway. 

Classical LDS genes 

The classical LDS genes are the TGFßR1 and TGFßR2 genes. These encode the receptors which initiate the TGFß pathway. The TGFß pathway is responsible for regulating several cellular processes:

• Cell growth 
• Differentiation of cells 

The disruption of the TGFß pathway prevents normal cell growth and forms abnormal tissue. This results in an aortic wall that tears and experiences aneurysms, and gives rise to skeletal abnormalities.³

Non-canonical LDS Genes

On the other hand, some genes are part of the LDS pathway but do not follow the typical functional route. These are known as non-canonical LDS genes. What makes them “non-canonical”? The genes have different combinations of coding regions joined together during transcription; this process is called splicing. As a result, different proteins are produced from the same gene.³

Furthermore, there is translation of non-canonical open reading frames- ORFs. ORFs are sections of the genes that are not typically coded for. However, in non-canonical ORF translation, these regions are translated and produce proteins that contribute to LDS. 

Both these non-canonical pathways include gene variants such as:

• Splice variants in FBN1 greatly impact the function of the FBN1 protein. This protein is essential for the composition of connective tissue
• Translation of non-canonical ORFs in the ASNSD1 gene contributes to muscle development³

The SMAD family and TGF-β signalling

Overview of the TGFß pathway 

The TGFß signalling pathway is involved in multiple cellular processes, such as:

• Cell growth 
• Differentiation 
• Cell death 
• Tissue repair 
• Homeostasis - maintaining a stable and regular environment 

Disruption in this pathway has global effects across the body’s internal systems. To better understand the genetic basis of LDS, we must understand the TGFß signalling pathway. 

Cells signal through ligands and receptors. Each type of ligand binds to a specific receptor. In the case of the TGFß pathway, the TGFß ligands bind to the TGFß receptors (TGFßR). The pathway is initiated through ligand binding to the TGFßRII, which activates TGFßRI through phosphorylation. This receptor is key in triggering the rest of the components in the pathway. 

There are two main pathways, non-canonical and canonical. Canonical pathways involve the SMAD family of signalling molecules. In contrast, the non-canonical uses other signalling molecules. This includes MAPK kinase pathways, involved in cell growth, proliferation and cell death. These kinase pathways are also used for direct gene repression or expression.⁴

SMAD2/3 Signalling

One of the main signalling molecules activated is the SMAD family ligands, specifically SMAD2 and SMAD3. These combine with the SMAD4 molecule and migrate to the nucleus. Here, they interact with transcription factors and DNA-binding proteins. This is crucial for regulating gene expression and protein transcription. The SMAD family is pivotal in ensuring cells undergo normal cell cycles. Interference in this pathway can have serious consequences, such as tumour development.⁴

SMAD2 and SMAD3 mutations in LDS

SMAD3 mutations are linked to LDS-III, which accounts for 5-10% of all LDS cases. The SMAD3 gene undergoes a loss-of-function mutation. This means the mutated gene produces a non-functional protein. Studies have shown that the SMAD3 mutation leads to fewer cells differentiating into the specific cells needed to maintain bone density. As a result, the skeletal structure becomes fragile and deforms. Additionally, the SMAD3 mutations cause abnormalities in the aorta and other blood vessels. Together, these changes to SMAD signalling have several impacts throughout the body, such as:⁵

• Aortic aneurysms 
• Aortic dissections
• Scoliosis - spinal deformation 
• Widely spaced eyes
• Cleft palate - a split in the roof of the mouth from incomplete tissue development
• Osteoarthritis - breakdown of cartilage in the joints

The SMAD2 protein is crucial for the TGFß signalling pathway and ensures the maintenance of tissue growth. Mutations of the SMAD2 gene lead to a dysfunctional SMAD2 protein and the development of LDS. A single inherited copy of this mutation can lead to the development of this condition.⁵

TGFB3 mutations and LDS type 5

The root cause of Type 5 LDS is mutations in the TGFß3 gene. TGFß3 gene mutations lead to changes in the TGFß ligand. As a result, the ligand can no longer bind to the corresponding TGFß receptor. This disturbs the natural signalling pathway, resulting in the typical cardiovascular, skeletal and facial characteristics associated with LDS. A person with type 5 LDS will experience the following symptoms:

• Aortic aneurysm 
• Tears in the aorta 
• Cleft palate 
• Skeletal overgrowth 
• Spine instability⁶

Genotype-phenotype correlations

There is a clear link between specific mutated genes and characteristics of LDS. Phenotypes are the visible characteristics caused by a gene. Various mutations lead to more severe phenotypes of LDS. 

TGFßR1 and TGFßR2 mutations are associated with more severe cardiovascular-related phenotypes. TGFßR2 is more closely linked to aortic phenotypes than TGFßR1. The mutation of these genes alters the composition of the aorta wall. Patients often have:

• Larger aortic dimensions 
• Aortic stiffness. 
• Scoliosis 
• Translucent skin 
• Easy bruising⁷

Furthermore, mutations in other genes, such as SMAD2 and SMAD3, change tissue properties. In contrast to TGFßR1/2, SMAD3 genes show mild cardiovascular complications. Patients with SMAD3 mutations often show:

• Facial deformities 
• Translucent skin 
• Cleft palate 
• Scoliosis⁷

Here, we can see a clear overlap of phenotypes between mutations. These patterns continue in other gene mutations, such as:

• The TGFß2 gene shows mild cardiovascular abnormalities and the typical translucent skin and scoliosis. The defining feature of this mutation is the spine instability and severe skeletal defects in the skull
• SMAD2 gene mutations show a broad range of features, ranging from aneurysms to coronary artery dissections⁷

Diagnostic and therapeutic implications

The typical route of diagnosis consists of a physical exam and a report on family history. If a doctor suspects LDS, then the patient will be referred to a geneticist. The geneticist specialises in genetic testing through blood tests and genetic screening. They use this to identify any mutations that could cause LDS.²

Due to the severe cardiovascular implications of this condition, further tests are done to support an LDS diagnosis:

• An echocardiogram is used to find any problems in the aorta or other heart defects 
• A computed tomography angiogram (CTA) or magnetic resonance angiogram (MRA) scan is done of the body from head to pelvis. This is done to identify any twists or aneurysms in the arteries²
• X-rays of the neck and spine are carried out to check for abnormalities that could be linked to LDS

Due to LDS’s genetic specificity, it can be used to produce targeted treatments for individual patients. The mutated genes act as therapeutic targets. Depending on the mutation and the corresponding type of LDS, researchers can create specific therapies to target them. However, due to the great overlapping of symptoms, it may prove difficult to distinguish and specify treatment. Therefore, the collaboration of multiple specialists is necessary to develop the most efficient and effective treatment plan for patients.

Conclusion

Recent genomic discoveries have significantly expanded our understanding of Loeys-Dietz Syndrome, particularly the mutations in SMAD2, SMAD3, and TGFB3. These gene mutations are the basis of dysregulated TGF-β signalling in the pathogenesis of LDS. This revealed a broader phenotypic range than previously recognised. Recent improvements in genetic characterisation enhance diagnostic accuracy and open new avenues for personalised care and targeted therapeutic interventions. Continued research into the molecular mechanisms and long-term outcomes associated with these variants will be essential for optimising clinical management and improving patient outcomes.